Grafa News and Videos — Page 761

Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) released updated Phase 1/2 clinical data for its experimental antibody-drug conjugate, CRB-701, demonstrating therapeutic activity in patients with pretreated, human papillomavirus (HPV)-associated solid tumors that express high levels of the Nectin-4 protein.

Performance Shipping (NASDAQ:PSHG) reported a 59% increase in first-quarter revenue for 2026, driven by a larger operational fleet and stronger charter rates that accelerated the company's operating cash generation.

Dyne Therapeutics (NASDAQ:DYN) submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration seeking conditional marketing clearance for z-rostudirsen, its investigational treatment targeting a specific subset of patients with Duchenne muscular dystrophy (DMD).

Virax Biolabs Group (NASDAQ:VRAX) announced positive preliminary performance metrics from an early pilot dataset for ViraxImmune™, its proprietary blood-based diagnostic test under development for Long COVID and related post-acute infection syndromes (PAIS).

Uni-Fuels Holdings (NASDAQ:UFG) raised its full-year revenue guidance after reporting sharp top-line expansion and volume growth for the first quarter of 2026, driven by a broad scale-up in global marine fuel trading and commercial market capture.

CSW Industrials (NYSE:CSW) reported record financial results for both the fourth quarter and the full fiscal year of 2026, navigating higher interest expenses and non-cash charges through a combination of aggressive acquisition integration and a return to organic expansion in its core segment.

Freightos (NASDAQ:CRGO) reported mixed financial and operational metrics for the first quarter of 2026, as geopolitical tensions and airspace restrictions across the Middle East slowed core transaction growth while simultaneously driving up global shipping rates to support the logistics platform's overall transaction value.

Genprex (NASDAQ:GNPX) announced the official abstract publication of positive clinical biomarker data for its lead oncology candidate, Reqorsa gene therapy (quaratusugene ozeplasmid), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.

iQSTEL (NASDAQ:IQST) reported a 69.9% surge in consolidated revenue for the first quarter of 2026, driven by consistent volume expansion across its core telecommunications subsidiaries and an increasingly meaningful operational lift from its newly integrated fintech assets.

Biohaven (NYSE:BHVN) released new clinical and safety data for opakalim, its selective Kv7.2/7.3 potassium channel activator, showing meaningful reductions in seizure frequency and a highly differentiated central nervous system safety profile across generalized and focal forms of epilepsy.